---
title: "Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China"
description: "Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276886600.md"
published_at: "2026-02-25T12:26:25.000Z"
---

# Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

### Related Stocks

- [600196.CN - FOSUN PHARMA](https://longbridge.com/en/quote/600196.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [02196.HK - FOSUN PHARMA](https://longbridge.com/en/quote/02196.HK.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/en/news/276549711.md) |
| HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/en/news/276700073.md) |
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/en/news/276765156.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.